UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/661,658	09/14/2000	Andrew D. Ellington	119927-1021	9207
	7590 02/01/200° N, COHN, FERRIS, GI	EXAMINER		
AND POPEO, F	P.C.	GIBBS, TERRA C		
ONE FINANCIAL CENTER BOSTON, MA 02111			ART UNIT	PAPER NUMBER
,		1635		
SHORTENED STATUTORY	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
3 MONTHS 02/01/2007		02/01/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Ty

		Application No.	Applicant(s)			
Office Action Summary		09/661,658	ELLINGTON ET AL.			
		Examiner	Art Unit			
· <del>-</del>		Terra C. Gibbs	1635			
The Period for Re	e MAILING DATE of this communication app ply	pears on the cover sheet with the c	orrespondence address			
WHICHEV - Extensions after SIX (6) - If NO period - Failure to re Any reply re	ENED STATUTORY PERIOD FOR REPLY (ER IS LONGER, FROM THE MAILING DATE of time may be available under the provisions of 37 CFR 1.13 MONTHS from the mailing date of this communication. If for reply is specified above, the maximum statutory period we ply within the set or extended period for reply will, by statute ceived by the Office later than three months after the mailing in term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from , cause the application to become ABANDONE!	lely filed the mailing date of this communication.  O (35 U.S.C. § 133).			
Status						
1)⊠ Res	ponsive to communication(s) filed on <u>19 Ja</u>	nnuary 2007.				
· <u> </u>	· · · · · · · · · · · · · · · · · · ·	action is non-final.	•			
3)☐ Sinc	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
close	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition o	f Claims					
	m(s) <u>7 and 21</u> is/are pending in the applica					
	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
·	6)  Claim(s) is/are rejected. 7)  Claim(s) <u>7 and 21</u> is/are objected to.					
	m(s) are subject to restriction and/or	r election requirement				
5/ <u>1</u>	(-) and dasjoin to recall and in an area	oloston roquitornont.				
Application P	apers					
9)⊠ The s	specification is objected to by the Examine	r.				
10)⊠ The drawing(s) filed on <u>14 September 2000</u> is/are: a) accepted or b)⊠ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)∐ The c	path or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.			
Priority under	35 U.S.C. § 119	•				
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of:						
1.	1. Certified copies of the priority documents have been received.					
2.	2. Certified copies of the priority documents have been received in Application No					
3.□	3. Copies of the certified copies of the priority documents have been received in this National Stage					
	application from the International Bureau (PCT Rule 17.2(a)).					
* See the attached detailed Office action for a list of the certified copies not received.						
	·					
Attachment(s)						
	eferences Cited (PTO-892) aftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary ( Paper No(s)/Mail Da				
3) 🔲 Information	Disclosure Statement(s) (PTO/SB/08)	5) 🔲 Notice of Informal Pa				
Paper No(s)/Mail Date 6)						

### **DETAILED ACTION**

# Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on January 19, 2007 has been entered.

Claims 7 and 21 are pending in the instant application.

Claim 21 has been amended.

Claims 7 and 21 have been examined on the merits.

#### Response to Arguments

Applicants Amendment and Remarks filed January 19, 2007 have been considered. Rejections and/or objections not reiterated from the previous office action mailed December 16, 2005 are hereby withdrawn. The following rejections and/or objections are either newly applied or are reiterated and are the only rejections and/or objections presently applied to the instant application.

#### **Drawings**

The drawings filed on September 14, 2000 are acknowledged. The drawings are objected to because the description of the drawings indicates that such material may very well be critical to determining whether there exists adequate description and

Art Unit: 1635

enablement of the instant invention. In brief, Figure 1, regions P1 and P6, and Figures 2a (photograph) and 2b (photograph) are sufficiently poor enough that it is difficult to determine what is actually being described. Any structural detail that is essential for a proper understanding of the disclosed invention should be shown in the drawing. MPEP § 608.02(d). Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as "amended." If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either "Replacement Sheet" or "New Sheet" pursuant to 37 CFR 1.121(d). If the changes are not accepted by the Examiner, the Applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance.

### Specification

The disclosure is objected to because of the following informalities: Throughout the specification, particularly pages 10, 38, and 39 make reference to "Figure 3a",

"Figure 3b", and "Figure 4a", where only "Figure 3" and "Figure 4" have been disclosed in the Drawings section of the instant specification. Appropriate correction is required.

### Claim Objections

Claims 7 and 21 are objected to because of the following informalities: As written, claims 7 and 21 recite the limitation, "or an oligonucleotide sequence that hybridizes under stringent conditions to a hybridization probe the nucleotide sequence of which comprises the sequence of SEQ ID NO:2 or an oligonucleotide that is complementary or antisense to such a probe". This limitation does not flow very well in the claims and the Examiner is suggesting the insertion of commas after the terms "hybridization probe" and "SEQ ID NO:2". This suggestion or some other form of appropriate correction is required.

# Allowable Subject Matter

It is noted that the art does not teach or fairly suggest an allosterically regulatable aptazyme oligonucleotide comprising a Group I intron oligonucleotide and an aptamer oligonucleotide, wherein the kinetic parameters of the Group I intron oligonucleotide vary in response to the interaction of an allosteric effector molecule with the aptamer oligonucleotide and wherein the aptazyme comprises SEQ ID NO:2, or an oligonucleotide sequence that hybridizes under stringent conditions to a hybridization probe, the nucleotide sequence of which comprises SEQ ID NO:2, or an oligonucleotide that is complementary or antisense to such a probe.

Art Unit: 1635

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Terra C. Gibbs whose telephone number is 571-272-0758. The examiner can normally be reached on 9 am - 5 pm M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Schultz can be reached on 571-272-0763. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

wh C. Dal

tcg January 26, 2007